Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
Showing 1–60 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
…hort 1 has 43 patients all with HLA A2 receiving ipilimumab and nivolumab with 10 doses of intra-muscular SCIB1 over 24-months. Cohort 3 …
… with treatment-naïve, stage IV NSQ NSCLC without AGAs received STK-012 subcutaneously (SC) Q3W + standard of care pembrolizumab, pemet…
…y signals. These preliminary data support further evaluation of ruxolitinib as an adjunctive therapy for severe CIP. ClinicalTrials.gov Ide…
… levels of Bacteroides and Desulfovibrionaceae, suggesting that BJIKT created a favorable microbial environment for antitumor immunit…
…01 is a promising novel immunotherapy strategy to treat cancer. RIDE-001’s pharmacological activity translates across primary human immu…
…tics (PK), pharmacodynamics (PD), and clinical activity of both AB598 monotherapy and AB598 in combination with zimberelimab (anti-PD…
…F-κB signaling, thereby suppressing MDSCs migration.Conclusions SUSD2 boosts antitumor immunity via a TRAF2/NF-κB/CXCL1 axis to inhib…
…d PFS in combination with trastuzumab (T), ramucirumab (R), and paclitaxel (P) in advanced, previously treated HER2+ gastric/gastroesophag…
…ety signals after 9 months of follow-up.All 7 patients received A2B694, were efficacy-evaluable, and had A2B694 detected post-infusion…
…mary objective of dose escalation is to determine MTD and RP2D. Pembrolizumab (200 mg IV) will be given with micvo at escalating doses starti…
…tribution of immune and tumor cells in the TME as a response to ZM008 treatment. Key inclusion criteria: histologically confirmed adv…